Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs.
Evan Y Yu, Christian Gratzke, Mauricio Burotto...
https://pubmed.ncbi.nlm.nih.gov/41732008/Actively Recruiting
Led by Merck Sharp & Dohme LLC · Updated on 2026-11-03
1310
Participants Needed
288
Research Sites
80 weeks
Total Duration
Researchers are evaluating the drug opevesostat in comparison to alternative hormonal therapies abiraterone acetate or enzalutamide for adults with metastatic castration-resistant prostate cancer mCRPC who have previously been treated with next-generation hormonal agents and taxane-based chemotherapy. This phase 3, randomized, open-label study aims to determine if opevesostat improves overall survival in participants both with and without androgen receptor ligand binding domain mutations. Participants are randomly assigned to receive either opevesostat 5 mg orally twice daily combined with dexamethasone 1.5 mg once daily and fludrocortisone acetate 0.1 mg once daily, or alternative therapies consisting of abiraterone 1000 mg once daily with prednisone 5 mg twice daily, or enzalutamide 160 mg once daily. Hydrocortisone is provided as rescue medication as needed. Treatment continues until disease progression. During the study, participants undergo regular assessments including monitoring overall survival, radiographic progression-free survival, time to subsequent therapies, response duration, pain progression, prostate-specific antigen levels, and safety evaluations for adverse events. The study may last up to approximately 54 months for key outcome measures, with ongoing monitoring to assess treatment effects and participant safety throughout the trial.
CONDITIONS
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
T
Toll Free Number
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Merck Sharp & Dohme LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Opevesostat | Alternative NHA (standard AR pathway inhibitor) |
|---|---|---|
| What it is | An investigational oral steroidogenesis inhibitor targeting CYP11A1 (opevesostat, MK‑5684) being tested in patients with mCRPC who progressed on prior hormonal therapy | An active comparator arm using an alternative next‑generation hormonal agent, either abiraterone acetate or enzalutamide given orally |
| Role in the trial | Experimental treatment under investigation | Active comparator using existing hormonal therapy |
| Primary use or purpose | To assess whether Opevesostat improves overall survival and radiographic progression‑free survival compared to standard hormonal therapy in mCRPC | To serve as the standard therapy benchmark of abiraterone acetate or enzalutamide for evaluating Opevesostat |
| Administration method | Orally administered steroidogenesis inhibitor | Oral administration of either abiraterone acetate or enzalutamide |
| Evidence status | Efficacy in survival and progression outcomes is currently under investigation in phase III trial | Abiraterone acetate and enzalutamide have demonstrated overall survival benefit in mCRPC patients |
| Important known risks | Safety profile under investigation; no published safety data yet | Known side effects include hypertension, liver enzyme elevations, fatigue with abiraterone or enzalutamide |
| Important limitations | Unknown clinical efficacy and safety until trial results are available | Resistance often develops and previous exposure may limit effectiveness |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 54 months
Participants receive either opevesostat with dexamethasone and fludrocortisone acetate or alternative hormonal therapies including abiraterone acetate with prednisone or enzalutamide until their disease progresses.
Regular visits as scheduled by the study
Duration - Up to approximately 54 months
Participants are monitored for overall survival, progression, response, pain levels, PSA changes, and safety outcomes after treatment ends.
Periodic visits for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Evan Y Yu, Christian Gratzke, Mauricio Burotto...
https://pubmed.ncbi.nlm.nih.gov/41732008/Merck Sharp & Dohme LLC
Lead Sponsor